1. Generics Bulletin
  2. >>Policy & Regulation

Medicines For Europe Calls For Security Of Supply Legislation

Increasing Inflation And Potential Price Cuts May Otherwise Impede Access

 
• By Chloe Kent

Medicines for Europe has urged the European Commission to enshrine security of supply considerations for essential medicines into legislature. Without these, additional cost containment measures for off-patent medicines under consideration by member states may ultimately threaten access by making production unsustainable for manufacturers.

EU flag locked door padlock
Medicines for Europe has called for security of supply considerations to be brought into essential medicines legislature • Source: Alamy

Medicines for Europe has called upon the European Commission to integrate security of supply considerations into the EU Transparency Directive and the Public Procurement Directive to protect access to essential medicines, which it says is under threat from a combination of increasing inflation and potential further price cuts across EU member states. The former directive governs medicines pricing and reimbursement decisions while the latter governs medicine tendering.

Several countries across the region are currently considering additional cost containment measures for off-patent medicines, which Medicines for Europe says could limit access to these drugs

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Generics Bulletin

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.